Enabling Flexibility And Scientific Innovation In Oral Solid Dose (OSD) Development

Early drug development rarely stalls for lack of a promising compound. It stalls at formulation. Poor solubility, unpredictable stability, and the pressure to build scalable manufacturing processes while clinical priorities shift are where timelines erode and resources run thin. For clinical-stage biotechs with limited runway, a CDMO partnership that combines technical depth with genuine flexibility isn't just convenient; it's a material risk factor.

This case study follows Cerevance, a Boston-based biotech developing cell-type-specific treatments for CNS disorders, through the formulation and process development challenges that defined their clinical path. It explores how the partnership structure itself shaped their ability to adapt, and what that means for other biotechs navigating similar early-stage decisions. Explore the full case study to see how the partnership unfolded.